To the best of our knowledge, this is the first clinical trial to report the efficacy and safety of an EGFR/CD3 bispecific antibody combined with PD-1 antibody and chemotherapy among NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.